Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Eisai Europe

Listen to the podcast

 

In this educational podcast, Veerle Lamotte and Paola Belardi share their successful experience of managing patients treated with VEGFR-TKIs for select solid tumours.

The short 15-minute discussion captures and provides you with their useful insight on:

1. The safety profile of VEGFR-TKIs alone or in combination with PD-1 inhibitors in hepatocellular cancer (HCC), differentiated thyroid cancer (DTC) & advanced renal cell carcinoma (RCC) and how to recognise side effects & understand appropriate management

2. How to best manage patients both prior to & during treatment to ensure optimal treatment success, including prehabilitation of patients prior to treatment & management of side effects on treatment

Veerle and Paola have many years nursing experience and present views not only from the perspective of the nurse, but also with relevance across geographies.

This is the first collaboration between GI NURSES CONNECT and GU NURSES CONNECT on an educational programme offering a valuable resource that is not limited to one tumour type.

This GI NURSES CONNECT and GU NURSES CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

Veerle Lamotte has worked as an oncology nurse practitioner at Antwerp University Hospital since 2013. She graduated as a nurse in 2001, working initially in intensive care before moving to work in oncology in 2010. Veerle supports and guides patients within the tumour cluster uro-oncology care process; from diagnosis, during treatment, follow-up phase and at relapse.  As an oncology nurse she has detailed knowledge and experience of urology, oncology and palliative care. Veerle is also a board member of UROBEL (the Belgian National Association for Urological Nurses) which keep nurses in Belgium informed about new strategies in uro-oncological healthcare. 

Veerle Lamotte has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Ipsen and Pfizer. 

Paola Belardi is a Nurse Co-ordinator at San Donato Hospital in Arezzo, Italy. Paola gained her first level Nursing Degree at the University of Siena in 2000. Later, in 2002 she attended a Public Health class at the University of Florence and in 2010 she graduated the Master Degree in Management at the University of Siena. In 2013 she started her work in oncology setting and now she is principally committed in activities such as nurse staffing and quality standard in oncology. From 2018 she is also an adjunct professor teaching Oncology Nursing at the University of Siena. Her professional interests are: chemotherapy and target therapy side effects management, intravenous devices management and nurses education. In the last month she has been co-supervisor of two Nursing Degree thesis: one studying the nurses’ role in fatigue prevention and the other regarding the nurses’ level of knowledge about simultaneous care model.

Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Eisai Europe

Listen to the podcast

 

In this educational podcast, Veerle Lamotte and Paola Belardi share their successful experience of managing patients treated with VEGFR-TKIs for select solid tumours.

The short 15-minute discussion captures and provides you with their useful insight on:

1. The safety profile of VEGFR-TKIs alone or in combination with PD-1 inhibitors in hepatocellular cancer (HCC), differentiated thyroid cancer (DTC) & advanced renal cell carcinoma (RCC) and how to recognise side effects & understand appropriate management

2. How to best manage patients both prior to & during treatment to ensure optimal treatment success, including prehabilitation of patients prior to treatment & management of side effects on treatment

Veerle and Paola have many years nursing experience and present views not only from the perspective of the nurse, but also with relevance across geographies.

This is the first collaboration between GI NURSES CONNECT and GU NURSES CONNECT on an educational programme offering a valuable resource that is not limited to one tumour type.

This GI NURSES CONNECT and GU NURSES CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

Veerle Lamotte has worked as an oncology nurse practitioner at Antwerp University Hospital since 2013. She graduated as a nurse in 2001, working initially in intensive care before moving to work in oncology in 2010. Veerle supports and guides patients within the tumour cluster uro-oncology care process; from diagnosis, during treatment, follow-up phase and at relapse.  As an oncology nurse she has detailed knowledge and experience of urology, oncology and palliative care. Veerle is also a board member of UROBEL (the Belgian National Association for Urological Nurses) which keep nurses in Belgium informed about new strategies in uro-oncological healthcare. 

Veerle Lamotte has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Ipsen and Pfizer. 

Paola Belardi is a Nurse Co-ordinator at San Donato Hospital in Arezzo, Italy. Paola gained her first level Nursing Degree at the University of Siena in 2000. Later, in 2002 she attended a Public Health class at the University of Florence and in 2010 she graduated the Master Degree in Management at the University of Siena. In 2013 she started her work in oncology setting and now she is principally committed in activities such as nurse staffing and quality standard in oncology. From 2018 she is also an adjunct professor teaching Oncology Nursing at the University of Siena. Her professional interests are: chemotherapy and target therapy side effects management, intravenous devices management and nurses education. In the last month she has been co-supervisor of two Nursing Degree thesis: one studying the nurses’ role in fatigue prevention and the other regarding the nurses’ level of knowledge about simultaneous care model.

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Clinical insights and expert discussion

Experts
Prof. Domenica Lorusso, Prof. Jean-Sebastien Frenel
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2026

This programme has been sponsored by PMV Pharma and is intended for HCPs only.